Compare Stocks: XFOR, CGEM, ORIC, and VOR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$16.87 -22.2%	$19.85	$5.68 ▼ $23.19	$1.39B	0.02	895,414 shs	2.59 million shs
ORIC Oric Pharmaceuticals	$13.33 -1.3%	$12.68	$7.23 ▼ $14.93	$1.40B	1	1.22 million shs	1.72 million shs
VOR Vor Biopharma	$19.37 -12.0%	$22.11	$6.50 ▼ $49.95	$1.30B	1.71	1.04 million shs	2.76 million shs
XFOR X4 Pharmaceuticals	$3.11 -9.3%	$3.93	$2.80 ▼ $4.83	$340.07M	0.39	910,878 shs	2.31 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	+1.50%	+5.50%	-0.05%	+22.78%	+245.06%
ORIC Oric Pharmaceuticals	+6.55%	+9.22%	-4.93%	+43.16%	+24.77%
VOR Vor Biopharma	+0.50%	-1.43%	-5.82%	+51.70%	-21.23%
XFOR X4 Pharmaceuticals	-1.72%	-5.25%	-15.10%	-16.14%	+1.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$16.87 -22.2%	$19.85	$5.68 ▼ $23.19	$1.39B	0.02	895,414 shs	2.59 million shs
ORIC Oric Pharmaceuticals	$13.33 -1.3%	$12.68	$7.23 ▼ $14.93	$1.40B	1	1.22 million shs	1.72 million shs
VOR Vor Biopharma	$19.37 -12.0%	$22.11	$6.50 ▼ $49.95	$1.30B	1.71	1.04 million shs	2.76 million shs
XFOR X4 Pharmaceuticals	$3.11 -9.3%	$3.93	$2.80 ▼ $4.83	$340.07M	0.39	910,878 shs	2.31 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	+1.50%	+5.50%	-0.05%	+22.78%	+245.06%
ORIC Oric Pharmaceuticals	+6.55%	+9.22%	-4.93%	+43.16%	+24.77%
VOR Vor Biopharma	+0.50%	-1.43%	-5.82%	+51.70%	-21.23%
XFOR X4 Pharmaceuticals	-1.72%	-5.25%	-15.10%	-16.14%	+1.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	2.78	Moderate Buy	$33.00	95.61% Upside
ORIC Oric Pharmaceuticals	2.80	Moderate Buy	$20.18	51.40% Upside
VOR Vor Biopharma	2.91	Moderate Buy	$43.38	123.93% Upside
XFOR X4 Pharmaceuticals	2.50	Moderate Buy	$11.25	261.74% Upside

Current Analyst Ratings Breakdown

Latest XFOR, CGEM, ORIC, and VOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	ORIC Oric Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$26.00
9/16/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
9/14/2026	CGEM Cullinan Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/25/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	CGEM Cullinan Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00
8/13/2026	CGEM Cullinan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$39.00 ➝ $42.00
8/12/2026	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $27.00
8/11/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D+)
8/11/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$6.92 per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	$35.11M	8.78	N/A	N/A	$2.13 per share	1.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$219.88M	-$3.10	N/A	N/A	N/A	N/A	-52.89%	-48.18%	11/5/2026 (Estimated)
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	11/12/2026 (Estimated)
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	-$79.20M	-$1.20	N/A	N/A	N/A	-568.80%	-63.05%	-36.89%	11/4/2026 (Estimated)

Latest XFOR, CGEM, ORIC, and VOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	VOR Vor Biopharma	-$0.69	-$0.80	-$0.11	-$1.16	N/A	N/A
8/6/2026	Q2 2026	CGEM Cullinan Therapeutics	-$0.7993	-$0.81	-$0.0107	-$0.81	$3.67 million	N/A
8/6/2026	Q2 2026	XFOR X4 Pharmaceuticals	-$0.1760	-$0.13	+$0.0460	-$0.13	$2.42 million	$8.81 million
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	8.42	8.42
ORIC Oric Pharmaceuticals	N/A	13.19	13.19
VOR Vor Biopharma	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	0.49	11.30	11.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
ORIC Oric Pharmaceuticals	95.05%
VOR Vor Biopharma	97.29%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	8.60%
ORIC Oric Pharmaceuticals	5.70%
VOR Vor Biopharma	0.27%
XFOR X4 Pharmaceuticals	1.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	109	64.36 million	58.82 million	Optionable
ORIC Oric Pharmaceuticals	111	103.65 million	97.75 million	Optionable
VOR Vor Biopharma	76	59.16 million	59.00 million	N/A
XFOR X4 Pharmaceuticals	45	99.15 million	98.03 million	No Data

XFOR, CGEM, ORIC, and VOR Headlines

Recent News About These Companies

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Moderate Buy" by Brokerages

September 18, 2026 | americanbankingnews.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $11.25 Consensus Price Target from Brokerages

September 16, 2026 | defenseworld.netD

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Rating of "Moderate Buy" from Analysts

September 13, 2026 | marketbeat.com

X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

September 11, 2026 | zacks.com

XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets

September 11, 2026 | marketbeat.com

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

September 9, 2026 | globenewswire.com

X4 Pharmaceuticals Announces Positive Outcome From FDA Type C Meeting And Provides Update On 4WARD Phase 3 Chronic Neutropenia Trial

September 8, 2026 | marketscreener.comM

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

September 8, 2026 | globenewswire.com

Braidwell LP Sells 350,200 Shares of X4 Pharmaceuticals, Inc. $XFOR

September 3, 2026 | marketbeat.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | globenewswire.com

X4 Pharmaceuticals (NASDAQ:XFOR) President Sells $109,117.44 in Stock

August 14, 2026 | insidertrades.com

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

August 11, 2026 | zacks.com

X4 Pharmaceuticals (XFOR) Receives a Buy from Stifel Nicolaus

August 9, 2026 | theglobeandmail.com

X4 Pharmaceuticals: Q2 Earnings Snapshot

August 6, 2026 | chron.com

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026 | markets.businessinsider.com

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

X4 Pharmaceuticals, Inc. Common Stock (XFOR) After Hours Quote

July 13, 2026 | nasdaq.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 7, 2026 | globenewswire.com

X4 Pharmaceuticals (NASDAQ:XFOR) CFO David Kirske Sells 8,543 Shares

July 2, 2026 | insidertrades.com

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

July 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR, CGEM, ORIC, and VOR Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$16.87 -4.80 (-22.15%)

Closing price 04:00 PM Eastern

Extended Trading

$17.38 +0.50 (+2.99%)

As of 07:58 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Oric Pharmaceuticals NASDAQ:ORIC

$13.33 -0.17 (-1.26%)

Closing price 04:00 PM Eastern

Extended Trading

$13.32 -0.01 (-0.08%)

As of 07:30 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Vor Biopharma NASDAQ:VOR

$19.37 -2.63 (-11.95%)

Closing price 04:00 PM Eastern

Extended Trading

$19.33 -0.04 (-0.19%)

As of 07:59 PM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

X4 Pharmaceuticals NASDAQ:XFOR

$3.11 -0.32 (-9.33%)

Closing price 04:00 PM Eastern

Extended Trading

$3.14 +0.03 (+0.93%)

As of 07:54 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XFOR, CGEM, ORIC, and VOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XFOR, CGEM, ORIC, and VOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XFOR, CGEM, ORIC, and VOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR, CGEM, ORIC, and VOR Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

Oric Pharmaceuticals NASDAQ:ORIC

Vor Biopharma NASDAQ:VOR

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XFOR, CGEM, ORIC, and VOR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XFOR, CGEM, ORIC, and VOR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XFOR, CGEM, ORIC, and VOR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR, CGEM, ORIC, and VOR Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

Oric Pharmaceuticals NASDAQ:ORIC

Vor Biopharma NASDAQ:VOR

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools